Non-Clear Cell Kidney Cancer Clinical Trials

Last Updated: March 8th, 2019

Click on the NCI Trial ID to learn more about each trial including eligibility criteria and information about enrollment. Listing a study is not an endorsement of any clinical trial. 

To submit a new a clinical trial or make a correction, please contact:
NCI Trial IDHistologyTreatmentPhaseLocations
NCT02724878Non-clear Cell RCC[Atezolizumab + bevacizumab] (immunotherapy + targeted therapy)IIMI, CA, MA
NCT03075423 SUNIFORECASTNon-clear Cell RCC[Ipilimumab + nivolumab] vs. sunitinib (immunotherapy or targeted therapy VEGF inhibitor)IIGermany
NCT02915783Non-clear Cell RCC
(Not recruiting since 1/30/19)
[Lenvatinib + everoliumus] (targeted therapy VEGF inhibitor + m-TOR inhibitor)IIFL, IL, MA, MO, TX, UT
NCT03177239 UNISoNNon-clear Cell RCCNivolumab followed by [nivolumab + ipilimumab] (sequential immunotherapy)IIAustralia
NCT03635892Non-Clear Cell RCC[Nivolumab + cabozantinib] (immunotherapy + targeted therapy)IINJ, NY
NCT03685448 UNICABNon-clear Cell RCC
(Not yet recruiting as of 3/8/19)
Cabozantinib (targeted therapy)IIAustralia
NCT02626130Non-Clear Cell & Clear Cell RCCTremelimumab with or without cryoablation (immunotherapy in patients undergoing surgery)IHouston, TX
NCT02996110 FRACTION-RCCNon-Clear Cell & Clear Cell RCC[Nivolumab + ipilimumab] or [nivolumab + relatlimab] or [nivolumab + BMS-986205] (immunotherapy + targeted therapy IDO1 inhibitor)II19 states in U.S., Australia, Austria, Canada, Israel, Italy
NCT03117309Non-Clear Cell & Clear Cell RCCNivolumab and [nivolumab + ipilimumab] (combination immunotherapy)IIDC, IL, MA, NJ, NY, OH, PA, TX
NCT03435640 REVEALNon-Clear Cell & Clear Cell RCC
(It has been reported that some institutions may not be accepting non-clear cell patients)
[NKTR262 + NKTR 214] (combination immunotherapy)I/IIAZ, FL, GA, OR, TX
NCT01638533Non-Clear Cell & Clear Cell RCCRomidepsin (targeted therapy HDAC inhibitor)ICA, GA, IL, MD, MI, MN, OH, PA, WI, Canada
NCT02655822Non-Clear Cell & Clear Cell RCCCPI-444 or [CPI-444 + atezolizumab] (immunotherapy A2A checkpoint inhibitor + PD-L1 checkpoint inhibitor)IAZ, CA, CO, CT, DC, GA, IL, MD, MA, MI, MO, NE, NY, NC, OH, PA, TX, WI, Australia, Canada
NCT02646748Non-Clear Cell & Clear Cell RCC[Pembrolizumab + itacitinib] or [Pembrolizumab + INCB050465] (Immunotherapy + JAK1 inhibitor or PI3K-delta inhibitor)ICA, DC, FL, MD, MA, MI, MO, NY, NC, PA. TX, UT
NCT02950766Non-Clear Cell & Clear Cell RCC (Not yet recruiting as of 3/8/19)[NeoVax + ipilimumab] (personalized cancer vaccine and immunotherapy)IMA
NCT02298959Non-Clear Cell & Clear Cell RCC[Pembrolizumab + ziv-aflibercept] (immunotherapy + chemotherapy)IFL, MD, MA, Canada
NCT03024437Non-Clear Cell & Clear Cell RCC[Atezolizumab + bevaciuzmab + entinostat] or [atezolizumab + entinostat] (immunotherapy + targeted therapy VGEF & HDAC inhibitors)I/IIIN, PA
NCT03111901Non-Clear Cell & Clear Cell RCC[Pembrolizumab + low-dose interleukin-2] (immunotherapy checkpoint inhibitor and cytokine)I/IIVA
NCT02718066Non-Clear Cell & Clear Cell RCC[HBI-8000 + nivolumab] (immunotherapy + targeted therapy HDAC inhibitor)I/IIAZ, CA, FL, MD, TX
NCT03115801Non-Clear Cell & Clear Cell RCCNivolumab or [Nivolumab + radiation] (immunotherapy with or without radiation)IINY
NCT03149822Non-Clear Cell & Clear Cell RCC[Pembrolizumab + cabozantinib] (immunotherapy and targeted therapy)I/IICO
NCT03633110Non-Clear Cell & Clear Cell RCC (Adjuvant Therapy & Metastatic Disease)GEN-009 Adjuvanted Vaccine or [Nivolumab + GEN-009 Adjuvanted Vaccine] (personalized cancer caccine and/or immunotherapy)I/IIAZ, CA, CO, MA, MI. NY, PA, TN, TX
NCT03055013 PROSPER RCCNon-Clear Cell & Clear Cell RCC (Neoadjuvant Therapy - Non-metastatic)Nivolumab prior to and after nephrectomy (neoadjuvant immunotherapy)III38 states in U.S.
NCT02721732Non-Clear Cell, Clear Cell RCC & Renal Medullary CarcinomaPembrolizumab (immunotherapy)IIHouston, TX
NCT02619253Non-Clear Cell & Clear Cell RCC and Urothelial Carcinoma[Pembrolizumab +Vorinostat]
(Immunotherapy + HDAC Inhibitor)
NCT02495103Non-Clear Cell & Clear Cell RCC (Including HLRCC)[Vandetanib + Metformin] (targeted therapy + blood glucose regulator)I/IIBethesda, MD (NIH)
NCT01130519Papillary RCC (Including HLRCC)[Bevacizumab + erlotinib] (targeted therapy combination)IIBethesda, MD (NIH)
NCT02019693Papillary RCCCapmatinib (INC280) (targeted therapy MET inhibitor)IIBethesda, MD (NIH)
NCT02761057Papillary RCCCabozantinib or crizotinib or volitinib vs. sunitinib (targeted therapy MET inhibitors vs. VEGF inhibitor)II37 states in U.S. and Canada
NCT02819596 CALYPSOPapillary RCC[Durvalumab (MEDI4736) + savolintinib] (immunotherapy + targeted therapy)IIUK and Spain
NCT03319628Papillary RCCXMT-1536 (immunoconjugate therapy)IMA, OK, PA, SC, TN, TX
NCT03091192Papillary RCC (MET gene driven) (Not recruiting since 1/18/19)Savolitinib vs. sunitinib (targeted therapy)III12 states in U.S., Brazil, France, Italy, Korea, Russia, Ukraine
NCT03175224Papillary or Clear Cell RCC (MET gene driven)CBT-101 (targeted therapy c-MET inhibitor)IAZ, CA, FL, MN
NCT03866382Papillary RCC, Chromophobe RCC, Sarcomatoid RCC and Renal Medullary Carcinoma
(Not yet recruiting as of 3/8/19)
[Nivolumab + ipilimumab + cabozantinib] (combination immunotherapy and targeted therapy)IITBD
NCT02363751 BEVABELCollecting Duct RCC[Gemcitabine + platinum + bevacizumab] (chemotherapy + targeted therapy)IIFrance
NCT03595124Xp11.2 Translocation[Nivolumab + axitinib] or axitinib or nivolumab (immunotherapy and/or targeted therapy)II25 states in U.S.
NCT03401788VHL-Associated RCC
(Not recruiting since 2/1/19)
PT2977 (targeted therapy HIF-2α inhibitor)II11 states in U.S., Denmark, France, Netherlands, UK,
NCT03165721HLRCC-Associated RCCGuadecitabine (SGI-110) (DNA methyltransferase inhibitor)IIBethesda, MD (NIH)
NCT03274258Renal Medullary Carcinoma (RMC)[Nivolumab + ipilumumab] (combination immunotherapy)IIHouston, TX
NCT02496208Renal Medullary Carcinoma, Sarcomatoid RCC, Clear Cell RCC, and Other Rare Kidney Cancer Histology[Nivolumab + cabozantinib] or [nivolumab + ipilimumab + cabozantinib] (immunotherapy + targeted therapy)ICA, MD, NJ, OH
NCT02601950Renal Medullary Carcinoma and Malignant Rhabdoid Tumor with INI1 (SMARCB1) loss (Ages 16+)Tazemetostat (targeted therapy EZH2 inhibitor)II12 states in U.S., Australia, Belgium, Canada, France, Germany, Italy, Taiwan, UK
NCT03587662Renal Medullary Carcinoma and other tumors with loss of SMARCB1; including adult-onset rhabdoid tumorsIxazomib, Gemcitabine and Doxorubicin (chemotherapy + targeted therapy)IIHouston, TX
NCT03213665Renal Medullary Carcinoma, Wilms’ Tumor and Rhabdoid Tumor with SMARCB1, SMARCA4, or EZH2 loss (Ages 1-21)
(Suspended as of 3/8/19)
Tazemetostat (targeted therapy EZH2 inhibitor)II33 states in U.S.
NCT03541902Variant histology RCC (vhRCC) Including Papillary RCC, Chromophobe RCC, Xp11.2 Translocation, Undifferentiated and Unclassified RCCCabozantinib or sunitinib (targeted therapy)IIHouston, TX
NCT02465060 MATCHGenetic Based Kidney Cancer (Therapy directed by genetic testing)22 different targeted therapy agents for EGFR, HER2, MET, ALK, ROS1, BRAF, PIK3CA, mTOR, TSC1, TSC2, PTEN, NF1, GNAQ, GNA11, SMO, PTCH1, NF2, cKIT, FGFR, DDR2 S768R, I638F, L239R, AKT, NRAS, CCND, CDK4, CDK6, MLH, NTRK, BRCA gene mutationsII50 states in the U.S.

Lost Password


Subscribe for updates!